Kranjin is primarily studied for its potential antiviral properties, particularly against the dengue virus. It has shown inhibitory effects on dengue virus replication in vitro, making it a subject of interest in the development of treatments for dengue fever. The compound is derived from natural sources, specifically from the bark of the Ceriops tagal plant, which is traditionally used in some folk medicines. Due to its bioactive nature, kranjin is investigated as a lead compound in antiviral drug research, especially in regions where dengue is endemic. Its application remains mainly in the preclinical research stage, focusing on understanding its mechanism of action and potential for structural optimization to enhance efficacy and reduce toxicity.